Search

Displaying results 5611 - 5620 of 10000 in total
  1. Drug

    IDM-4

    go.drugbank.com/drugs/DB05438
    Experimental

    IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia. … It is a monoclonal antibody-specific antigen that can selectively target cancer-affected cells by coupling with tumor cell-killing MAK cells, which are derived from the patient's own monocytes.

  2. Drug

    Pimagedine

    go.drugbank.com/drugs/DB05383
    Investigational

    It is beneficial in treating patients with diabetic nephropathy. … It is an advanced glycation end product inhibitor which manages diabetic nephropathy, either alone or in combination with other therapies.

  3. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    It is developed for the treatment of obesity and other metabolic disorders.

  4. Drug

    Quinisocaine

    go.drugbank.com/drugs/DB13683
    Experimental

    Categories: Anesthetics for Topical Use
  5. Drug

    MLN576

    go.drugbank.com/drugs/DB06517
    Experimental

    XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II.[A234609]

  6. Drug

    Lexatumumab

    go.drugbank.com/drugs/DB06599
    Investigational

    Lexatumumab is a fully humanized, high-affinity immunoglobulin G(1 lambda) monoclonal antibody (mAb).

  7. Drug

    Pentolinium

    go.drugbank.com/drugs/DB01090
    Approved

    Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.

  8. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  9. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

  10. Drug

    Oxeladin

    go.drugbank.com/drugs/DB04822
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1976 due to carcinogenicity.